A new set of disease management tools has just been released at the BIO International Congress in San Diego. The new disease management solution includes a patient app, healthcare provider interface and analytics dashboard designed to provide biopharma and medtech companies with pre-built, regulatory compliant digital tools to improve patient engagement, symptom management and Treatment compliance, and equipment.
new Disease Management Solutions, based on BrightInsight’s compatible platform (built on Google Cloud Platform), provides applications that customers can easily configure to support improved communication with patients and providers. The platform is designed to help patients take their medication on time and take the appropriate dose, provide detailed data on the impact of treatment and track a patient’s overall quality of life.
“We developed this disease management solution to help biopharmaceutical and medical technology companies bring their software as a medical device (SaMD) to market faster,” said BrightInsight CEO and co-founder Dr. Kal Patel. “This provides companies with a proven template to develop unique digital products that will transform the way their patients manage their conditions…and add more value to their treatments.”
Digital needs in a competitive market
BrightInsight’s new solution is the company’s latest offering to help biopharma and medtech companies jumpstart their digital health offerings. In 2021 alone, BrightInsight completed seven SaMDs for its biopharmaceutical clients.
BrightInsight’s solutions are growing in popularity, giving companies more flexibility to build, scale and maintain regulated digital health products without having to deal with the growing pains associated with in-house development.
“It can be a daunting task for companies to create these digital solutions themselves,” Patel said. “They may not have the experience to understand all the nuances of the field, which can really slow them down – it usually takes three to four years to get to the market on their own. Even after the initial delay, their struggles may be over. Just getting started. For example, the platform may not scale across products and geographies. We address these challenges by creating products that are compliant, highly secure, ensure patient privacy, and have built-in scalability. We don’t let our customers paint themselves in a corner.”
This is not an abstract need. Companies are increasingly motivated to pursue digital solutions. Many patients struggle to comply with their treatment regimens, costing the biopharmaceutical industry more than $600 billion annually. Digital products have enormous potential to help solve this and other problems.
“The biopharmaceutical industry is leveraging data and digital technologies to accelerate drug development, increase treatment adherence and durability, and improve the patient journey, driving the explosive growth of the regulated digital health market, which is expected to reach 560 million by 2025. billion,” said Karl Hick, former chief digital and information officer at Takeda and member of the BrightInsight Advisory Board. “For biopharmaceuticals to efficiently and effectively build and launch regulated digital solutions, it is critical that partners such as BrightInsight have the experience and proven platforms and solutions to ensure compliance with way to massively accelerate time-to-market.”
Additionally, digital disease management creates an important point of contact with payers, providers, and especially patients. Even frequent doctor visits cannot provide all the necessary support to help patients manage chronic conditions. Connected 24/7, digital tools can enhance the continuity of care and provide patients with consistent guidance. Additionally, physicians can receive real-time data to track patients more closely, resolve issues as they arise and potentially prevent hospitalizations.
“Sanofi believes that digital innovation can transform the discovery, development and delivery of medicines. Digitalisation is at the heart of our work to deliver a better patient experience, improve disease management and build a deeper relationship between patients and healthcare providers Connect. The data collected through these efforts will also help drive more personalized treatments, deliver services that go beyond the pill, and potentially extend the patent life of our most valuable brands,” said Global Head, Digital Innovation and Patient Services, Immunology Brad Gescheider speaks at Sanofi. “We’ve partnered with BrightInsight to build a next-generation digital disease management solution that will allow us to impact every step of the patient journey.”
At the same time, SaMD and other digital tools are emerging as key differentiators in the market. With an increasingly competitive environment and a demanding reimbursement market, companies are looking for digital platforms that can give them a competitive advantage.
“That’s how companies can personalize treatment,” Patel said, “to help ensure the right patients get the right treatment and support their adherence and persistence and help them manage their condition effectively. Disease management is this A very promising use case for this technology – we’re seeing it in oncology, rare disease, immunology, chronic care.”
A model of success
Digital tools have become especially valuable for people with rare diseases that can be particularly difficult to manage. In some cases, the drug regimen is so strict that it must be followed. Digital platforms can help ease this burden, providing medication reminders, symptom management, and secure communication with clinicians.
BrightInsight recently collaborated with Chinese Super League Belin Creating a digital application for adult patients taking Hizentra® for primary immunodeficiency (PID) and chronic inflammatory demyelinating polyneuropathy (CIDP). Patients taking Hizentra received multiple daily subcutaneous infusions, which can make compliance a challenge.
The app allows patients to closely track their infusions, receive timely reminders, and share their medication logs with their doctors. So far, more than 3,000 patients have downloaded the Hizentra app, This represents a good cross-section of Hizentra patients, The app has an App Store rating of 4.5+ stars.
“Patients taking Hizentra must self-inject multiple times a day, and it’s critical that they track exactly when and where these injections are,” Patel said. “We built this solution with CSL Behring and it really helps reduce the burden of disease management for these patients. That’s how we want to model these solutions. By helping companies better engage with patients, we Give everyone the information they need to improve their health.”
photo: imtmphoto, Getty Images
